Michael R. Zile

3 weeks ago | jacc.org | Milton Packer |Michael R. Zile |Christopher M. Kramer |Masahiro Murakami

References1. "Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction". Circ Heart Fail . 2013;6:279-286. 2. "The association of obesity and cardiometabolic traits with incident HFpEF and HFrEF". JACC Heart Fail . 2018;6:701-709. 3. "Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction". Circulation . 2017;136:6-19. 4.

Dec 9, 2024 | onlinelibrary.wiley.com | Muhammad Khan |Baylor Scott |Michael R. Zile

Introduction The global prevalence of atrial fibrillation (AF) is approximately 50 million, and it is estimated that in the US alone, 16 million people may have AF by 2050.1 As almost one third of the AF population is asymptomatic and has paroxysmal episodes, the worldwide AF burden is most likely under-estimated.2, 3 AF frequently co-exists with heart failure (HF) with each disease predisposing to the other.

May 17, 2024 | cfrjournal.com | Harriette Van Spall |Mark C. Petrie |Michael R. Zile |Muthiah Vaduganathan

HFA 24 - We are joined onsite by Dr Michael Zile (Medical University of South Carolina, US) to discuss the outcomes of the RELIEVE-HF trial. RELIEVE-HF is designed to evaluate the safety and effectiveness of the V-Wave interatrial shunt system in patients with heart failure.